Sadly, I don't have a book to recommend. Most of the targeting today is happening through antibodies, but the majority of LNP delivery at this point is done pa

Sadly, I don't have a book to recommend. Most of the targeting today is happening through antibodies, but the majority of LNP delivery at this point is done passively without targeting mechanisms on the LNP (Needle injection point aside). That's actually one advantage of CRISPR over just injecting mRNA - you can target specific cell-lines (Even if you change the genome of many cell types) by using cell-specific promoters for the edits you make instead of relying on surface affinity based targeting of the LNP. Interesting resources: [0]: https://www.nature.com/articles/nrd.2017.243 https://www.nature.com/articles/nrd.2017.243 (General review 1) [1]: https://www.frontiersin.org/articles/10.3389/fmolb.2020.587997/full https://www.frontiersin.org/articles/10.3389/fmolb.2020.5879... (General review 2) [2]: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5498813/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5498813/ (PCSK9 target again, but via siRNA actuator) [3]: https://genomebiology.biomedcentral.com/articles/10.1186/s13059-015-0715-0 https://genomebiology.biomedcentral.com/articles/10.1186/s13... (Example of cell-specific CRISPR integration)